Company news

Denali Therapeutics Inc. news in 2026

Denali Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

November 3, 2026

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

October 30, 2026

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

October 22, 2026

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

August 6, 2026

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

July 27, 2026

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

July 9, 2026

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

June 18, 2026

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

May 20, 2026

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

May 7, 2026

Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm)

April 20, 2026

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV: PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

April 2, 2026

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

March 24, 2026

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

February 26, 2026

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

February 5, 2026

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

February 1, 2026

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

January 28, 2026

Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

January 5, 2026

Calls in 2026

Decks in 2026